{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:17Z","timestamp":1793212157967,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The benefit of continuing 5-aminosalicylates (5-ASA) in patients with ulcerative colitis (UC) escalated to advanced therapies remains uncertain. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of 5-ASA continuation vs discontinuation in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched the PubMed, Embase, and Cochrane databases for studies comparing 5-ASA continuation vs discontinuation in adult patients with UC escalated to advanced therapies. Adjusted effect estimates were pooled using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The meta-analysis comprised nine observational cohorts and two studies presenting post-hoc analyses from eight clinical trials. We included 11\u2009487 patients, with 9105 assigned to 5-ASA continuation and 2382 to 5-ASA discontinuation. Compared to discontinuation, 5-ASA continuation was associated with decreased odds of achieving clinical remission (adjusted odds ratio [aOR] 0.72; 95% CI 0.52-0.99; I2\u2009=\u20090%). There were no significant differences between groups for corticosteroid-free clinical remission (aOR 0.71; 95% CI 0.41-1.23; I2\u2009=\u20090%), clinical response (aOR 0.94; 95% CI 0.69-1.28; I2\u2009=\u20090%), endoscopic healing (OR 1.00; 95% CI 0.71-1.41; I2\u2009=\u200954.6%), and biochemical remission (aOR 1.13; 95% CI 0.76-1.68; I2\u2009=\u200931%). In time-to-event analyses, no significant differences were found between groups for UC-related hospitalization (adjusted hazard ratio [aHR] 0.99; 95% CI 0.86-1.13; I2\u2009=\u20090%), UC-related surgery (aHR 1.02; 95% CI 0.80-1.29; I2\u2009=\u200913%), new corticosteroid prescription (aHR 0.97; 95% CI 0.88-1.07; I2\u2009=\u20090%), composite adverse events (aHR 0.96; 95% CI 0.87-1.06; I2\u2009=\u20090%), and loss of response (aHR 0.92; 95% CI 0.75-1.12; P\u2009=\u2009.39; I2\u2009=\u200961%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with UC escalated to advanced therapies, 5-ASA continuation was associated with decreased odds of achieving clinical remission compared to discontinuation, with no significant differences observed for secondary efficacy or safety endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf202","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T12:59:13Z","timestamp":1764421153000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of 5-aminosalicylic acid continuation versus discontinuation in patients with ulcerative colitis escalated to advanced therapy: a systematic review and meta-analysis of adjusted effect estimates"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5930-268X","authenticated-orcid":false,"given":"Hyun Hee","family":"Sul","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Jersey City Medical Center\/Rutgers Health , Jersey City, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas Mesadri","family":"Gewehr","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paran\u00e1 , Curitiba, Paran\u00e1,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hara","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odery","family":"Ramos","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Internal Medicine and Health Sciences, Federal University of Paran\u00e1 , Curitiba, Paran\u00e1,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-3758","authenticated-orcid":false,"given":"Ryan C","family":"Ungaro","sequence":"additional","affiliation":[{"name":"The Dr Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, and University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre , Manitoba,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2025121502120438300_jjaf202-B1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"2025121502120438300_jjaf202-B2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Berre","year":"2023","journal-title":"The \u00adLancet"},{"key":"2025121502120438300_jjaf202-B3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/MIB.0000000000001152","article-title":"Modified Delphi process for the development of choosing wisely for inflammatory bowel disease","volume":"23","author":"Nguyen","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025121502120438300_jjaf202-B4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.51.4.536","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"51","author":"Ransford","year":"2002","journal-title":"Gut"},{"key":"2025121502120438300_jjaf202-B5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.14309\/ajg.0000000000000847","article-title":"Cost-effectiveness of 5-aminosalicylate therapy in combination with biologics or tofacitinib in the treatment of ulcerative colitis","volume":"116","author":"Shaffer","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2025121502120438300_jjaf202-B6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA Living Clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"2025121502120438300_jjaf202-B7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/gutjnl-2018-317021","article-title":"Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts","volume":"68","author":"Ungaro","year":"2019","journal-title":"Gut"},{"key":"2025121502120438300_jjaf202-B8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/apt.15876","article-title":"Benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy","volume":"52","author":"Singh","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121502120438300_jjaf202-B9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41395-018-0144-2","article-title":"No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy: pooled analysis of individual participant data from clinical trials","volume":"113","author":"Singh","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2025121502120438300_jjaf202-B10","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"key":"2025121502120438300_jjaf202-B11","first-page":"1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025121502120438300_jjaf202-B12","doi-asserted-by":"publisher","author":"Wohlin","year":"2014","DOI":"10.1145\/2601248.2601268"},{"key":"2025121502120438300_jjaf202-B13","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"2025121502120438300_jjaf202-B14","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ."},{"key":"2025121502120438300_jjaf202-B15","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2025121502120438300_jjaf202-B16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2025121502120438300_jjaf202-B17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J Educ Behav Stat"},{"key":"2025121502120438300_jjaf202-B18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025121502120438300_jjaf202-B19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"2025121502120438300_jjaf202-B20","author":"Rohatgi","year":"2021"},{"key":"2025121502120438300_jjaf202-B21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"Stat Methods Med Res"},{"key":"2025121502120438300_jjaf202-B22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2025121502120438300_jjaf202-B23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2025121502120438300_jjaf202-B24","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023"},{"key":"2025121502120438300_jjaf202-B25","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"2025121502120438300_jjaf202-B26","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ecco-jcc\/jjad113","article-title":"Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in inflammatory bowel disease: post hoc analyses of clinical trial data","volume":"17","author":"Ungaro","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025121502120438300_jjaf202-B27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.18102","article-title":"Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study","volume":"60","author":"Seo","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121502120438300_jjaf202-B28","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1093\/ibd\/izaf001","article-title":"Impact of 5-aminosalicylic acid on ustekinumab in inflammatory bowel disease: a retrospective medical claims analysis","volume":"31","author":"Nishida","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025121502120438300_jjaf202-B29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jgh.16786","article-title":"Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis","volume":"40","author":"Nishida","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"2025121502120438300_jjaf202-B30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ygh2.391","article-title":"Aminosalicylate withdrawal following escalation to immunomodulators or biologics in ulcerative colitis: cost saving, convenient and does not compromise efficacy","volume":"2","author":"Nicolaides","year":"2020","journal-title":"GastroHep"},{"key":"2025121502120438300_jjaf202-B31","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.cgh.2018.11.062","article-title":"Concomitant use of aminosalicylates is not associated with improved outcomes in patients with ulcerative colitis escalated to vedolizumab","volume":"17","author":"Ma","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121502120438300_jjaf202-B32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00384-019-03368-1","article-title":"Comparison of outcomes of continuation\/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease","volume":"34","author":"Choi","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"2025121502120438300_jjaf202-B33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/apt.16518","article-title":"Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study","volume":"54","author":"Bernstein","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121502120438300_jjaf202-B34","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1007\/s10620-020-06704-6","article-title":"Concomitant 5-aminosalicylate therapy in moderate-to-severe ulcerative colitis patients escalated to infliximab is not beneficial","volume":"66","author":"Balram","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2025121502120438300_jjaf202-B35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000527452","article-title":"Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis","volume":"104","author":"Mikami","year":"2023","journal-title":"Digestion"},{"key":"2025121502120438300_jjaf202-B36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/apt.14023","article-title":"Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease","volume":"45","author":"Bonovas","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121502120438300_jjaf202-B37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ibd.20074","article-title":"5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease","volume":"13","author":"Terdiman","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2025121502120438300_jjaf202-B38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.dld.2021.01.012","article-title":"From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies","volume":"53","author":"Fantini","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2025121502120438300_jjaf202-B39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-0037-1602237","article-title":"Colorectal cancer in inflammatory bowel disease","volume":"31","author":"Stidham","year":"2018","journal-title":"Clin Colon Rectal Surg"},{"key":"2025121502120438300_jjaf202-B40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000353806","article-title":"5-Aminosalicylic acid and chemoprevention: does it work?","volume":"31","author":"Lopez","year":"2013","journal-title":"Dig Dis"},{"key":"2025121502120438300_jjaf202-B41","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2012.198","article-title":"5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations","volume":"107","author":"Nguyen","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2025121502120438300_jjaf202-B42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2025121502120438300_jjaf202-B43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41591-023-02217-7","article-title":"Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease","volume":"29","author":"Mehta","year":"2023","journal-title":"Nat Med"},{"key":"2025121502120438300_jjaf202-B44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5217\/ir.2019.00084","article-title":"5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis","volume":"18","author":"Mizuno","year":"2020","journal-title":"Intest Res"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf202\/65672877\/jjaf202.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/11\/jjaf202\/65672877\/jjaf202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/11\/jjaf202\/65672877\/jjaf202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:12:20Z","timestamp":1765782740000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf202\/8362867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf202","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"jjaf202"}}